Dogs receiving the canine-specific CD200-directed inhibitor and the autologous tumor lysate had significanlty longer survivals (median 12.7 months) compared to a historical control group of dogs treated with surgery and autologous tumor lysate (median 6.4 months). Here, CD200 is linked to neoplasm.